



## **MEDIA ADVISORY**

10 June 2014

### **Sequella CEO Delivers Keynote Address at McGill International TB Center in Montreal Canada**

Rockville, Md. -- Sequella, Inc., a privately-held clinical stage company focused on commercializing novel treatments for antibiotic-resistant infectious diseases announced that its CEO, Dr. Carol Nacy, delivered a Keynote Address at the 3<sup>rd</sup> Annual Research Trainee Day at the McGill International TB Center, McGill University, Montreal, Quebec, Canada. Research Day showcases the vital contributions of the students and post-doctoral fellows in the Institute by poster and oral presentations. The focus of the meeting was on tuberculosis and other mycobacterial research.

The title of Dr. Nacy's lecture was "*Creating a Pipeline of Novel TB Drugs: Lessons Learned*," and was particularly relevant because of the recently-announced hospitalization of a visitor to the U.S. from India with extremely drug-resistant TB. After traveling in the U.S., this visitor was admitted to the National Institutes of Health Clinical Center, Bethesda, Maryland, where physicians from the National Institute of Infections and Autoimmune Diseases (NIAID) will treat her infection over the next year or more. There are few remaining drugs that are effective in treating extremely drug-resistant TB. Sequella is developing two new TB drugs with novel mechanisms of action that may provide better therapeutic options for such patients in the future.

#### **About McGill International TB Centre**

The McGill International TB Centre, situated at the McGill University Health Centre in Montreal, Canada, brings together more than 20 investigators working both at an Academic Center and with a number of collaborative groups around the world. The Centre includes researchers interested in biomedical, clinical, epidemiological, and social determinants of TB, and is a world leader in the interdisciplinary study of TB. Our work aims to develop and evaluate new diagnostic tests, new vaccines and new treatment regimens for the control of TB and other mycobacterial diseases. Director: Marcel Behr, MD, Ph.D.

#### **About Sequella**

Sequella is a privately-held clinical stage anti-infectives company focused on commercializing novel treatments for antibiotic-resistant infectious diseases. The company has been in operation for 18 years and has drugs in Phase 2 clinical trials for gastritis (*Helicobacter pylori*) and TB (Phase 2) and in IND-directed preclinical development for *Clostridium difficile* infections. Sequella leverages its global influence, R&D platforms, and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity. [www.sequella.com](http://www.sequella.com)

**Sequella Media Contact:** Alicia Moran, AMMedia  
[aliciamoranmedia@gmail.com](mailto:aliciamoranmedia@gmail.com)